New research indicates that people who stop using popular slimming jabs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt conventional diet and exercise programs.
Research printed in a leading health publication shows that while obese individuals can lose substantial amounts of their body weight while on the medication, the mass returns at an average rate of 0.8 kg per month once they quit.
"People using such medications must be cognizant of the potential of quick rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to pre-treatment mass within about a year and a half.
Weighing Treatments
The study, which reviewed 37 of trials involving thousands of participants, contrasted the results of GLP-1 agonists with other pills.
The team point out that people who shed pounds through dieting typically experience a slower creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Quick Regain
Nutrition scientists believe the mechanism of the drugs explains the amplified regain.
GLP-1 drugs copy a natural hormone called GLP-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is no longer kept in check, making excessive eating much more probable."
An Ongoing Disease?
Health authorities advise the injections for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
Professionals argue that, given the high risk of relapse, the therapy is often long-term.
This perspective is echoed by pharmaceutical companies, who note that the findings "emphasize the persistent nature of obesity," akin to managing diseases like high blood pressure.
User Experiences
Individuals who have stopped the medication explain a sudden return of cravings.
"I experienced something that goes on and I was suddenly ravenous," described an individual.
This challenge is compounded if patients have not established sustainable lifestyle or habit modifications during treatment.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Use is greater among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, clinicians stress that while these medications are potent tools for weight loss, they are not a permanent solution and lasting health benefits likely depends on integrated lifestyle management.
